OBJECTIVE: To determine the efficacy and safety of extended drotrecogin alfa (activated) (DAA) therapy. DESIGN: Multicentre, randomised, double-blind, placebo-controlled study. SETTING: Sixty-four intensive care units in nine countries. PATIENTS: Adults with severe sepsis and vasopressor-dependent hypotension after a 96-h infusion of standard DAA. INTERVENTIONS: A total of 193 patients received an intravenous infusion of extended DAA 24 microg/kg/h or sodium chloride placebo for a maximum of 72 h. MEASUREMENTS AND RESULTS: At extended therapy initiation (baseline), DAA-group patients had lower protein C levels (P = 0.23) and higher vasopressor requirements, particularly for the primary vasopressor used, norepinephrine (P = 0.03), compared with placebo-group patients. DAA treatment did not result in a difference in the primary outcome of time to resolution of vasopressor-dependent hypotension versus placebo (P = 0.419). However, few patients reached resolution (DAA 34%, placebo 40%) as most continued to require vasopressor support after 72 additional hours of treatment. Treatment did not reduce 28-day all-cause mortality and in-hospital mortality or improve organ function compared with placebo, although there was a lower percentage change in D-dimers (P < 0.001) and increases in protein C levels were numerically greater on extended infusion. There was no difference in serious adverse events including bleeding events. CONCLUSIONS: Extended DAA treatment did not result in more rapid resolution of vasopressor-dependent hypotension, despite demonstrating anticipated biological effects on D-dimer and protein C levels. A reduced planned sample size combined with baseline imbalances in protein C levels and vasopressor requirements may have limited the ability to demonstrate a clinical benefit.
RCT Entities:
OBJECTIVE: To determine the efficacy and safety of extended drotrecogin alfa (activated) (DAA) therapy. DESIGN: Multicentre, randomised, double-blind, placebo-controlled study. SETTING: Sixty-four intensive care units in nine countries. PATIENTS: Adults with severe sepsis and vasopressor-dependent hypotension after a 96-h infusion of standard DAA. INTERVENTIONS: A total of 193 patients received an intravenous infusion of extended DAA 24 microg/kg/h or sodium chloride placebo for a maximum of 72 h. MEASUREMENTS AND RESULTS: At extended therapy initiation (baseline), DAA-group patients had lower protein C levels (P = 0.23) and higher vasopressor requirements, particularly for the primary vasopressor used, norepinephrine (P = 0.03), compared with placebo-group patients. DAA treatment did not result in a difference in the primary outcome of time to resolution of vasopressor-dependent hypotension versus placebo (P = 0.419). However, few patients reached resolution (DAA 34%, placebo 40%) as most continued to require vasopressor support after 72 additional hours of treatment. Treatment did not reduce 28-day all-cause mortality and in-hospital mortality or improve organ function compared with placebo, although there was a lower percentage change in D-dimers (P < 0.001) and increases in protein C levels were numerically greater on extended infusion. There was no difference in serious adverse events including bleeding events. CONCLUSIONS: Extended DAA treatment did not result in more rapid resolution of vasopressor-dependent hypotension, despite demonstrating anticipated biological effects on D-dimer and protein C levels. A reduced planned sample size combined with baseline imbalances in protein C levels and vasopressor requirements may have limited the ability to demonstrate a clinical benefit.
Authors: G R Bernard; J L Vincent; P F Laterre; S P LaRosa; J F Dhainaut; A Lopez-Rodriguez; J S Steingrub; G E Garber; J D Helterbrand; E W Ely; C J Fisher Journal: N Engl J Med Date: 2001-03-08 Impact factor: 91.245
Authors: Jean-Louis Vincent; Derek C Angus; Antonio Artigas; Andre Kalil; Bruce R Basson; Hassan H Jamal; Gerald Johnson; Gordon R Bernard Journal: Crit Care Med Date: 2003-03 Impact factor: 7.598
Authors: Edward Abraham; Pierre-François Laterre; Rekha Garg; Howard Levy; Deepak Talwar; Benjamin L Trzaskoma; Bruno François; Jeffrey S Guy; Martina Brückmann; Alvaro Rea-Neto; Rolf Rossaint; Dominique Perrotin; Armin Sablotzki; Nancy Arkins; Barbara G Utterback; William L Macias Journal: N Engl J Med Date: 2005-09-29 Impact factor: 91.245
Authors: Jean-François Dhainaut; S Betty Yan; Benjamin D Margolis; José A Lorente; James A Russell; Ross C Freebairn; Herbert D Spapen; Hanno Riess; Bruce Basson; Gerald Johnson; Gary T Kinasewitz Journal: Thromb Haemost Date: 2003-10 Impact factor: 5.249
Authors: Paul B Massion; Pierre Peters; Didier Ledoux; Valentine Zimermann; Jean-Luc Canivet; Pierre P Massion; Pierre Damas; André Gothot Journal: Intensive Care Med Date: 2012-06-27 Impact factor: 17.440
Authors: Dustin C Krutsinger; Kelly L O'Leary; Susan S Ellenberg; Cody E Cotner; Scott D Halpern; Katherine R Courtright Journal: Ann Am Thorac Soc Date: 2020-09
Authors: Massimo Antonelli; Elie Azoulay; Marc Bonten; Jean Chastre; Giuseppe Citerio; Giorgio Conti; Daniel De Backer; François Lemaire; Herwig Gerlach; Goran Hedenstierna; Michael Joannidis; Duncan Macrae; Jordi Mancebo; Salvatore M Maggiore; Alexandre Mebazaa; Jean-Charles Preiser; Jerôme Pugin; Jan Wernerman; Haibo Zhang Journal: Intensive Care Med Date: 2010-01-08 Impact factor: 17.440
Authors: Ville Pettilä; Peter Buhl Hjortrup; Stephan M Jakob; Erika Wilkman; Anders Perner; Jukka Takala Journal: Intensive Care Med Date: 2016-07-23 Impact factor: 17.440